Sharon Eccles Steele Center for Translational Medicine, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA
Auto-generated profile, based on publicly available information
Burt Richards
Sharon Eccles Steele Center for Translational Medicine, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA
There is a need for diverse molecular libraries for phenotype-selective and high-throughput screening. To make marine natural products (MNPs) more amenable to newer screening paradigms and shorten discovery time lines, we have created an MNP library characterized online using MS. To test the potential of the library, we screened a subset of the library in a phenotype-selective screen to identify compounds that inhibited the growth of BRCA2-deficient cells.
Two human tumor cell lines that are deficient in the mismatch repair protein hMSH2 show little or no increase in mutation rate relative to that of a mismatch repair–proficient cell line when the cells are maintained in culture conditions allowing rapid growth. However, mutations accumulate at a high rate in these cells when they are maintained at high density. Thus the mutator phenotype of some mismatch repair–deficient cell lines is conditional and strongly depends on growth conditions. These observations have implications for tumor development because they suggest that mutations may accumulate in tumor cells when growth is limited.
Significance: The chromosome 10q26 locus is the genetic region most strongly associated with elevated risk of age-related macular degeneration (AMD), but the underlying genetic defects initiating disease are unresolved. Using human-derived eye tissues, we demonstrate that mRNA encoding the serine protease, HTRA1, is reduced in the retinal pigment epithelium (RPE) of donors with risk-associated variants that disrupt a cis-regulatory element within the 10q26 locus. Consequentially, there is diminished HtrA1 protein within the RPE–Bruch’s membrane interface, the primary site of AMD initiation, with age. This indicates that HtrA1 functions to maintain the integrity of this interface during the aging process and that HtrA1 levels are impaired by chromosome 10q26 risk-associated variants. HtrA1 augmentation may be a viable therapeutic option for AMD.
1 March 2010 in Bioorganic & Medicinal Chemistry Letters